Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action
Molecules · 2023
DOI: 10.3390/molecules28248014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Svetlana Miroshnichenko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Interferon-alpha, Apolipoproteins A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by the Federal budget for the Program Fundamental Research of state academies of sciences ., Federal budget for the Program Fundamental Research of state academies of sciences.
Abstract (Originalsprache)
Recombinant human interferon alpha-2b (rIFN) is widely used in antiviral and anticancer immunotherapy. However, the high efficiency of interferon therapy is accompanied by a number of side effects; this problem requires the design of a new class of interferon molecules with reduced cytotoxicity. In this work, IFN was modified via genetic engineering methods by merging it with the blood plasma protein apolipoprotein A-I in order to reduce acute toxicity and improve the pharmacokinetics of IFN. The chimeric protein was obtained via biosynthesis in the yeast P. pastoris. The yield of ryIFN-ApoA-I protein when cultivated on a shaker in flasks was 30 mg/L; protein purification was carried out using reverse-phase chromatography to a purity of 95–97%. The chimeric protein demonstrated complete preservation of the biological activity of IFN in the model of vesicular stomatitis virus and SARS-CoV-2. In addition, the chimeric form had reduced cytotoxicity towards Vero cells and increased cell viability under viral load conditions compared with commercial IFN-a2b preparations. Analysis of the pharmacokinetic profile of ryIFN-ApoA-I after a single subcutaneous injection in mice showed a 1.8-fold increased half-life of the chimeric protein compared with ryIFN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal Research Center of Fundamental and Translational Medicine (FRC FTM), Timakova str., 2, 630117 Novosibirsk, Russia.
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
ORCID-Profile: Anastasiia Kotliarova
Förderung
- This research was supported by the Federal budget for the Program Fundamental Research of state academies of sciences .
- Federal budget for the Program Fundamental Research of state academies of sciences
Zitieren
APA
Miroshnichenko, S., Pykhtina, M., Kotliarova, A., Chepurnov, A., & Beklemishev, A. (2023). Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action. Molecules. https://doi.org/10.3390/molecules28248014
Vancouver
Miroshnichenko S, Pykhtina M, Kotliarova A, Chepurnov A, Beklemishev A. Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action. Molecules. 2023. doi:10.3390/molecules28248014
BibTeX
@article{Miroshnichenko2023,
author = {Miroshnichenko, Svetlana and Pykhtina, Mariya and Kotliarova, Anastasiia and Chepurnov, Alexander and Beklemishev, Anatoly},
title = {Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28248014}
}
EUVIMED